Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 232 (7%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3280 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (12%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-ACYCLOVIR OINTMENT | 5% | OINTMENT | Resolved | 2021-11-26 | 2021-12-23 | 150052 |
| APO-ACYCLOVIR OINTMENT | 5% | OINTMENT | Resolved | 2024-12-19 | 2025-08-01 | 246067 |
| APO-ACYCLOVIR OINTMENT | 5% | OINTMENT | Resolved | 2025-03-13 | 2025-08-01 | 252560 |
| APO-ACYCLOVIR OINTMENT | 5% | OINTMENT | Actual shortage | 2025-10-16 | 2025-11-27 | 269754 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2017-03-11 | 2017-06-05 | 633 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2017-05-10 | 2017-07-19 | 9849 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2017-06-19 | 2017-09-03 | 13300 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2017-08-08 | 2017-12-31 | 18512 |
| APO-ALENDRONATE | 5MG | TABLET | Resolved | 2017-10-11 | 2018-03-27 | 25204 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2018-04-04 | 2018-05-24 | 44966 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2018-05-15 | 2018-07-03 | 49415 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2018-07-04 | 2018-10-09 | 54162 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2018-08-27 | 2018-11-26 | 59284 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2019-06-12 | 2019-07-12 | 86271 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2021-07-09 | 2021-09-27 | 142269 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2021-11-22 | 2021-12-01 | 149699 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2022-06-06 | 2022-08-11 | 162080 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2022-07-11 | 2022-08-11 | 164370 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2023-09-07 | 2023-10-20 | 203837 |
| APO-ALENDRONATE/VITAMIN D3 | 70MG 2800UNIT | TABLET | Resolved | 2017-07-17 | 2018-04-06 | 15962 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-FENTANYL MATRIX | 100MCG | PATCH | Discontinued | 2018-02-23 | 2018-12-28 | 40741 |
| APO-FENTANYL MATRIX | 25MCG | PATCH | Discontinued | 2018-09-07 | 2018-09-15 | 60489 |
| APO-FENTANYL MATRIX | Discontinued | 2018-09-07 | 2018-09-15 | 60494 | ||
| APO-FENTANYL MATRIX | 75MCG | PATCH | Discontinued | 2018-09-07 | 2018-09-15 | 60497 |
| APO-FLUNISOLIDE NASAL SPRAY | 0.25MG | METERED-DOSE PUMP | Discontinued | 2018-02-26 | 2018-02-26 | 40965 |
| APO-FLUVOXAMINE | 100MG | TABLET | Discontinued | 2017-03-30 | 2018-02-05 | 4713 |
| APO-FLUVOXAMINE | 50MG | TABLET | Discontinued | 2017-03-30 | 2018-02-05 | 4716 |
| APO-GAIN LIQ 20MG/ML | 20MG | SOLUTION | Discontinued | 2018-02-26 | 2018-02-26 | 40997 |
| APO-GAIN LIQ 20MG/ML | 20MG | SOLUTION | Discontinued | 2019-01-02 | 2019-01-02 | 70815 |
| APO-GEMFIBROZIL | 600MG | TABLET | Discontinued | 2017-03-31 | 2017-03-31 | 4927 |
| APO-GEMFIBROZIL CAP 300MG USP | 300MG | CAPSULE | Discontinued | 2017-03-31 | 2018-12-07 | 4920 |
| APO-GEMFIBROZIL CAP 300MG USP | Discontinued | 2019-06-12 | 2019-06-12 | 86557 | ||
| APO-GLICLAZIDE | 80MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60512 |
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94446 | ||
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94449 | ||
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94452 | ||
| APO-HALOPERIDOL TAB 2MG | 2MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1084 |
| APO-HALOPERIDOL TAB 5MG | 5MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1087 |
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
| APO-HYDROMORPHONE CR | 6MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110959 |